First machine-learning (ML) platform developer Unlearn.AI has raised $12m in a Series A financing round led by 8VC with participation from all of the company’s existing investors.
Other participants in the financing round included DCVC, DCVC Bio and Mubadala Capital Ventures.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe financing is expected to accelerate the application of Unlearn’s ML technology to improve the effectiveness of clinical trials and achieve results.
Unlearn.AI’s ML platform develops ‘Digital Twin’ profiles. A Digital Twin is a comprehensive and computationally generated clinical record describing the outcomes if a specific patient had received a placebo.
Unlearn.AI founder and CEO Charles K Fisher said: “This new financing marks an important milestone in our growth and will contribute to the significant progress we are making with regulators and with our commercial partners, who are already running studies with Digital Twins and demonstrating their value in generating robust evidence and increasing the potential for trial success.
“Clinical trials are facing a number of persistent challenges that have only been exacerbated in recent weeks.”
The company’s DiGenesis process of the platform explores historical clinical trial datasets from a number of patients, disease-specific ML models, and severe statistical analysis to create digital records. These records match patients who are part of the investigational-treatment arm of trials.
Through this novel approach of generating control patient data, the ML platform developer aims to reduce the number of patients required to run a trial. The company also aims to maintain rigorous standards of evidence, as well as study randomisation and blinding.
Unlearn Advisory Board member and Clinical Innovation Partners founder Craig Lipset said: “Unlearn’s unique model has shown that it can provide realistic digital patient records to supplement actual control patients in Alzheimer’s Disease trials.
“This is a potential game-changer, not only in trial recruitment strategies, but also in the delivery of high-quality data that supports study confidence and success.”
In December last year, Unlearn.AI reported that its ML platform is capable of providing digital patient records designed to supplement actual control patients in clinical trials of Alzheimer’s disease.
